New York HIE goes live using InterSystems platform

The Healthcare Information eXchange of New York (HIXNY), which serves healthcare facilities and patients in 17 counties in the Albany region and northern New York, has implemented InterSystems' HealthShare as its health information exchange (HIE) platform.

HIXNY is a not-for-profit organization whose members include health plans in the Greater Capital Region and northern New York representing more than 400,000 members; major regional hospitals; physician groups representing 500 physicians; healthcare associations representing 56 hospitals and more than 30 health plans in New York state; a university/school of public health; a consumer advocacy group; and a business group comprised of Capital Region employers.

With the move from a legacy HIE platform to HealthShare, HIXNY is positioned to add new capabilities for the hundreds of clinicians who are currently accessing the network portal, according to InterSystems, of Cambridge, Mass. The platform uses Integrating the Healthcare Enterprise (IHE) profiles built around Continuity of Care Document (CCD) specifications for EHR integration.

Nearly 200,000 e-prescriptions have been written via the HIXNY network, which also makes accessible patient data such as medication and allergy history that are critical to optimal care delivery. The current focus is on providing laboratories with connectivity via HealthShare, according to InterSystems. Three laboratories representing four hospitals are channeling results, including microbiology, pathology and blood bank results, into the HIE network.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.